Drug Topics May 3, 2024
A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.
Since being signed into law in August 2022, the Inflation Reduction Act (IRA) is intended to provide “meaningful financial relief” for millions of Americans with Medicare coverage, through expanded benefits and lowered drug costs.1 Nearly 2 years after its passing, though, unanswered questions around how provisions of the IRA—in particular, the Medicare drug price negotiation program.
According to Corey Ford, Vice President of Reimbursement and Policy Insights at Cencora, stakeholders have been provided clarity around data submission that manufacturers must provide, as well as on what patient engagement sessions will look like. “But there’s really a lack of clarity right now on how...
Today's Sponsors
Today's Sponsor